4.7 Article

CircKIF4A promotes glioma growth and temozolomide resistance by accelerating glycolysis

期刊

CELL DEATH & DISEASE
卷 13, 期 8, 页码 -

出版社

SPRINGERNATURE
DOI: 10.1038/s41419-022-05175-z

关键词

-

资金

  1. Changsha Municipal Natural Science Foundation [kq2202431]
  2. Hunan Provincial Natural Science Foundation of China [2022JJ30904]

向作者/读者索取更多资源

Circular RNA circKIF4A is upregulated in glioma and plays a vital role in promoting glioma progression by binding miR-335-5p and upregulating ALDOA expression. Knockdown of circKIF4A reduces glioma cell proliferation, invasion, and enhances sensitivity to temozolomide treatment.
Circular RNAs (circRNAs) are a kind of noncoding RNAs that have different biological functions. CircRNAs play very important parts in the progression of cancers. Nevertheless, the exact mechanism and function of many circRNAs in glioma are not clear. In our study, circKIF4A was identified as a remarkably upregulated circRNA expressed in glioma tissues and cell lines. We performed loss-off function and gain-of-function experiments to inquire into the biological function of circKIF4A in the progression of glioma. We discovered that knockdown of circKIF4A remarkably decreased the proliferation and invasion ability of glioma cells. Moreover, subcutaneous tumorigenesis model and intracranial injection of orthotopic glioma model were established to investigate the functions of circKIF4A in vivo. Suppression of circKIF4A remarkably enhanced the sensitivity of glioma to temozolomide treatment. The glycolysis rate was accelerated by circKIF4A overexpression, which promoted glioma growth and temozolomide resistance. The glycolysis regulating enzyme ALDOA was regulated by circKIF4A through the mechanism of interactivity with miR-335-5p in glioma cells. In a word, our data showed that the upregulation of circKIF4A facilitates glioma progression by means of binding miR-335-5p and upregulating ALDOA expression.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据